FDA
-
-
-
-
-
-
-
Mirum presents new data on rare liver disease treatments at EASL congress
-
-
-
-
-
-
-
Mirum announces $600 million convertible notes offering due 2032
-
-
-
-
-
-
-
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
-
-
-
-
-
-
-
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
-
-
-
-
-
-
-
Mirum sues generic drugmakers over Livmarli patent infringement
-
-
-
-
-
-
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
325,887 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

